Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q2 2025 value amounting to $6.0 million.

  • Enanta Pharmaceuticals' Gains from Investment Securities rose 1369.37% to $6.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 1738.92%. This contributed to the annual value of $5.8 million for FY2025, which is 1109.18% up from last year.
  • According to the latest figures from Q2 2025, Enanta Pharmaceuticals' Gains from Investment Securities is $6.0 million, which was up 1369.37% from $6.0 million recorded in Q1 2025.
  • Enanta Pharmaceuticals' 5-year Gains from Investment Securities high stood at $6.0 million for Q1 2025, and its period low was $83000.0 during Q3 2023.
  • Moreover, its 5-year median value for Gains from Investment Securities was $4.0 million (2021), whereas its average is $3.1 million.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 9491.69% in 2021, then skyrocketed by 108674.7% in 2024.
  • Enanta Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $4.2 million in 2021, then plummeted by 80.25% to $825000.0 in 2022, then tumbled by 77.82% to $183000.0 in 2023, then skyrocketed by 198.91% to $547000.0 in 2024, then surged by 988.3% to $6.0 million in 2025.
  • Its last three reported values are $6.0 million in Q2 2025, $6.0 million for Q1 2025, and $547000.0 during Q4 2024.